Product image of Nubriveo (Brivaracetam) supplied by GNH India

Nubriveo

Active Ingredient:
Brivaracetam
Origin:
EU

Nubriveo (Brivaracetam)

Brivaracetam, the active ingredient in Nubriveo, is an antiepileptic presented as a strength/form for oral use. It treats focal onset seizures in patients who require adjunctive therapy. GNH India supplies Nubriveo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH India supplies Nubriveo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Ucb Pharma S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Brivaracetam is an antiepileptic medication that acts on neuronal excitability associated with seizure activity.

  • Focal onset seizures: Provides adjunctive seizure control when added to existing therapy.
  • Partial epilepsy: Reduces seizure frequency in patients with refractory partial epilepsy.
  • Adjunct therapy: Enhances overall seizure management as part of combination treatment.

How It Works

  • Brivaracetam binds selectively to the synaptic vesicle protein 2A (SV2A) in the central nervous system, modulating neurotransmitter release and stabilising neuronal firing. This high‑affinity interaction reduces hyper‑excitability that underlies seizure generation, providing antiepileptic activity without directly blocking ion channels.

Side Effects

Adverse reactions to brivaracetam are generally mild to moderate and vary among individuals.

Common Side Effects

  • Dizziness
  • Fatigue
  • Headache
  • Nausea
  • Somnolence
  • Irritability

Serious or Rare Side Effects

  • Severe allergic reaction (anaphylaxis)
  • Mood changes including depression or suicidal thoughts
  • Severe skin reactions such as Stevens‑Johnson syndrome
  • Hepatic enzyme elevation
  • Cardiac arrhythmia
  • Respiratory depression

Precautions & Warnings

When prescribing brivaracetam, clinicians should consider several safety aspects.

  • Renal impairment: Adjust dose in patients with severe renal dysfunction.
  • Hepatic impairment: Use caution in patients with liver disease.
  • Concomitant depressants: Monitor for enhanced sedation.
  • Pregnancy: Evaluate risk‑benefit, as safety data are limited.
  • Breastfeeding: Weigh potential infant exposure against maternal benefit.
  • Store at ambient temperature: keep in original packaging, protect from moisture and light.

Avoid Interactions

Brivaracetam may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • Carbamazepine: May lower brivarine levels, reducing seizure control.
  • Phenytoin: Increases metabolism of brivaracetam, potentially decreasing effectiveness.

Moderate Interactions (Monitor Closely)

  • Valproate: May increase brivaracetam plasma concentrations.
  • Benzodiazepines: Additive central nervous system depression.
  • Alcohol: Enhances sedative effects and dizziness.
  • CYP3A4 inhibitors: May raise brivaracetam levels modestly.
  • CYP3A4 inducers: May reduce brivaracetam exposure.

Frequently Asked Questions

Nubriveo contains brivaracetam, an antiepileptic indicated for adjunctive treatment of focal onset seizures in patients who need additional seizure control beyond their current regimen.

Brivaracetam binds with high affinity to the synaptic vesicle protein 2A (SV2A) in the brain, modulating neurotransmitter release and reducing neuronal hyper‑excitability that leads to seizures.

The prescribed dose of brivaracetam is individualized by a healthcare professional based on the patient’s clinical condition, prior therapy, and renal or hepatic function.

Safety data for brivaracetam in pregnancy and lactation are limited; clinicians should assess the potential benefits against possible risks and consider alternative therapies when appropriate.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with older agents such as carbamazepine, brivaracetam offers a more selective SV2A binding profile, which may result in fewer drug‑interaction concerns and a different side‑effect spectrum, though individual response varies.

Store Nubriveo at ambient temperature, below 25 °C, in its original packaging, protected from moisture and direct light to maintain product stability.

Nubriveo is taken orally, usually as a tablet or oral solution, and should be swallowed with water as directed by the prescribing clinician.

Serious risks include severe allergic reactions, mood changes such as depression or suicidal thoughts, rare skin reactions like Stevens‑Johnson syndrome, and potential hepatic enzyme elevations.

Patients with known hypersensitivity to brivaracetam or any component of the formulation, and those with uncontrolled severe hepatic impairment, should avoid using Nubriveo.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Brivaracetam

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT